Classes
Progesterone, Natural (OTC)
- Classes: Women’s Health, Herbals
progesterone intravaginal gel (Rx)
- Classes: Progestins;
- Vaginal Preparations, Other
progesterone micronized (Rx)
- Classes: Progestins
Description
Naturally occurring progestin administered orally,vaginally, and parenterally
Used to treat amenorrhea and abnormal uterine bleeding in women, and to prevent endometrial hyperplasia in postmenopausal women taking estrogen therapy, and off-label for premenstrual dysphoric disorder (PMDD)
Also used to prevent early pregnancy failure in women with corpus luteum insufficiency and to reduce the risk for preterm birth in women with single gestation pregnancy and a history of spontaneous preterm delivery
Indications
Contraindications
Pregnancy, hypersensitivity
Documented hypersensitivity to drug or excipients
Known or suspected malignancy of the breast or genital organ
Active arterial or venous thromboembolism or severe thrombophlebitis, or a history of these events
Liver disease, liver tumors
Undiagnosed abnormal vaginal bleeding
Known missed abortion or ectopic pregnancy
Adverse Effects
- Vaginal spotting
- Rash
- Edema
- Breast enlargement (40%)
- Breast tenderness (27%)
- Somnolence (27%)
- Cramps (15-26%)
- Mood swings (22-23%)
- Nausea (6-22%)
- Depression (11-19%)
- Dizziness (15-24%)
- Sleep disorder (18%)
- Perineal pain (17%)
- Nervousness (16%)
- Urinary difficulties (11%)
- Musculoskeletal pain (12%)
- Headache (13%)
- Breast pain (13%)
- Abdominal pain (5-12%)
- Headache (10-31%)
- Breast tenderness (16-27%)
- Dizziness (15-24%)
- Abdominal pain (10-20%)
- Depression (19%)
- Breast pain (6-16%)
- Viral disease (7-12%)
- Fatigue (8-9%)
- Nausea (8%)
- Mood swings (6%)
Warnings
Progesterone and progestins have been used to prevent miscarriage in women with a history of recurrent spontaneous pregnancy losses; no adequate evidence is available to show that they are effective for this purpose
Caution in patients with family history of breast cancer and or DVT/PE, current/history of depression, endometriosis, DM, HTN, bone mineral density changes, renal/hepatic impairment, bone metabolic disease, SLE; conditions exacerbated by fluid retention (eg, migraine, asthma, epilepsy).
The physician should be alert to the earliest manifestations of thrombotic disorders (thrombophlebitis, cerebrovascular disorders, pulmonary embolism, and retinal thrombosis); should any of these occur or be suspected, the drug should be discontinued immediately
The pretreatment physical examination should include special reference to breast and pelvic organs, as well as Papanicolaou smear
Discontinue if the following develop jaundice, visual problems (may cause contact lens intolerance), any signs of VTE, migraine with unusual severity, significant blood pressure increase, severe depression, increased risk of thromboembolic complications after surgery.
Discontinue 4 weeks before major surgery or prolonged immobilization. Patients on warfarin, oral anticoagulants (increase in anticoagulant dose may be warranted).
Some studies link OCP use with increased risk of breast cancer, whereas other studies have not shown a change in risk. Woman’s risk depends on conditions where naturally high hormone levels persist for long periods of time including early onset menstruation before age 12, late onset menopause, after age 55, first child after age 30, nulliparity.
Increased risk of cervical cancer with OCP use, however HPV remains as main risk factor for this cancer.; evidence suggests long-term use of OCPs, 5 or more years, may be associated with increased risk; increased risk of liver cancer with OCP use; risk increases with longer duration of OCP use.
Do not use other intravaginal meds 6 hr before or after progesterone vaginal
Pregnancy and Lactation
Pregnancy Category: avoid use
Lactation: N/A
Pregnancy Category: avoid use
Lactation: N/A
Pregnancy Category: B
Lactation: Possibly safe; use caution
Maximum Dosage
Dependent on indication for therapy, and dosage route/formulation selected.
Dependent on indication for therapy, and dosage route/formulation selected.
Dependent on indication for therapy, and dosage route/formulation selected.
Not indicated in prepubescent females.
How supplied
Progesterone
intravaginal gel
- 4%
- 8%
vaginal insert
- 100mg
capsule
- 100mg
- 200mg